Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRIAN D SORIN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1932229911
CMS profile
269665
Location
PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$2,431.56

124 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,431.56 124

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRIAN D SORIN

NPI 1932229911 · CMS profile ID 269665

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PLANO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932229911?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRIAN D SORIN, NPI 1932229911, CMS profile ID 269665. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932229911?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). BRIAN D SORIN, NPI 1932229911, CMS profile ID 269665. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932229911?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
BRIAN D SORIN, NPI 1932229911, CMS profile ID 269665, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 124 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1932229911?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

124 matching records · $2,431.56 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 124 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 124.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $18.6008/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031288967 CMS
Amgen Inc. $19.9508/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019840489 CMS
AbbVie Inc. $28.1208/04/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999075117 CMS
PFIZER INC. $0.6708/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049407187 CMS
PFIZER INC. $24.7708/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050519171 CMS
Ipsen Biopharmaceuticals, Inc $26.3107/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045414453 CMS
Ipsen Biopharmaceuticals, Inc $1.1907/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045414471 CMS
Amgen Inc. $17.9107/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019840485 CMS
Grifols USA, LLC $16.5007/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011872767 CMS
Merz Pharmaceuticals, LLC $38.4207/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048317683 CMS
Lilly USA, LLC $25.6707/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031276257 CMS
AbbVie Inc. $20.6707/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999075113 CMS
Novartis Pharmaceuticals Corporation $18.2807/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993381943 CMS
AbbVie Inc. $12.3106/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999075105 CMS
AbbVie Inc. $17.2906/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999075109 CMS
AbbVie Inc. $34.9606/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999075101 CMS
Lundbeck LLC $16.0606/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1032369393 CMS
Amgen Inc. $18.8706/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019840481 CMS
AbbVie Inc. $29.0606/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999075097 CMS
Amgen Inc. $4.2906/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019840477 CMS
Merck Sharp & Dohme LLC $20.9906/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048634477 CMS
Lilly USA, LLC $16.4005/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031296219 CMS
Genentech USA, Inc. $23.1405/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040316657 CMS
AbbVie Inc. $19.3505/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999075089 CMS
AbbVie Inc. $1.8205/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999075093 CMS
Axsome Therapeutics, Inc. $21.6605/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056130017 CMS
Harmony Biosciences LLC $13.4805/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1013695949 CMS
PFIZER INC. $2.5305/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050638699 CMS
Ipsen Biopharmaceuticals, Inc $19.9405/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045414465 CMS
Amgen Inc. $18.0005/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019840475 CMS
Novartis Pharmaceuticals Corporation $13.8605/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 993381937 CMS
Teva Pharmaceuticals USA, Inc. $21.6604/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056699659 CMS
AbbVie Inc. $20.4704/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999075085 CMS
Ipsen Biopharmaceuticals, Inc $27.1704/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045414441 CMS
PFIZER INC. $12.4204/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050372197 CMS
Teva Pharmaceuticals USA, Inc. $18.3704/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056699627 CMS
PFIZER INC. $11.5504/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049261147 CMS
Lilly USA, LLC $34.8104/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031280203 CMS
Amgen Inc. $19.9204/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019840471 CMS
PFIZER INC. $11.8404/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049247181 CMS
Genentech USA, Inc. $24.2303/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1040316669 CMS
Merz Pharmaceuticals, LLC $46.9303/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048317689 CMS
Teva Pharmaceuticals USA, Inc. $16.9803/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056699635 CMS
Teva Pharmaceuticals USA, Inc. $22.0003/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056699631 CMS
Ipsen Biopharmaceuticals, Inc $23.0803/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045414431 CMS
Ipsen Biopharmaceuticals, Inc $0.5103/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1045414437 CMS
Amgen Inc. $19.3503/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019840467 CMS
PFIZER INC. $17.2703/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1049418207 CMS
AbbVie Inc. $18.3102/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 999075081 CMS
PFIZER INC. $12.5302/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050678191 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12,610.91 216
PY2020 $9,441.42 136
PY2021 $8,166.40 201
PY2022 $3,052.83 147
PY2023 $2,431.56 124
PY2024 $3,014.02 138
PY2025 $2,176.47 114

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $49,917.41 44
PY2022 Principal investigator $285.00 1
PY2021 Principal investigator $11,215.21 2
PY2020 Principal investigator $968.72 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

44 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ipsen Innovation $1,359.26 12/30/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076245433
Principal investigator 1 Ipsen Innovation $895.09 12/30/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076245435
Principal investigator 1 Ipsen Innovation $895.09 10/28/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076244531
Principal investigator 1 Ipsen Innovation $938.98 10/28/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076244533
Principal investigator 1 Ipsen Innovation $1,889.24 10/28/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076244535
Principal investigator 1 Ipsen Innovation $2,413.95 10/28/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076244537
Principal investigator 1 Ipsen Innovation $70.49 10/28/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076244539
Principal investigator 1 Ipsen Innovation $70.49 10/28/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076244541
Principal investigator 1 Ipsen Innovation $70.49 10/28/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076244543
Principal investigator 1 Ipsen Innovation $70.49 10/28/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076244761
Principal investigator 1 Ipsen Innovation $150.00 10/25/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076244759
Principal investigator 1 Ipsen Innovation $90.00 10/25/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076244767
Principal investigator 1 Ipsen Innovation $150.00 10/25/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076244771
Principal investigator 1 Ipsen Innovation $90.00 10/10/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076244529
Principal investigator 1 Ipsen Innovation $300.00 10/10/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076244545
Principal investigator 1 Ipsen Innovation $150.00 10/10/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076244547
Principal investigator 1 Ipsen Innovation $300.00 10/10/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076244763
Principal investigator 1 Ipsen Innovation $180.00 10/10/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076244765
Principal investigator 1 Ipsen Innovation $300.00 10/10/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076244769
Principal investigator 1 Ipsen Innovation $70.49 08/12/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076248013
Principal investigator 1 Ipsen Innovation $70.49 08/12/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076248015
Principal investigator 1 Ipsen Innovation $150.00 07/31/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076243111
Principal investigator 1 Ipsen Innovation $90.00 07/17/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076243109
Principal investigator 1 Ipsen Innovation $150.00 07/17/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076243113
Principal investigator 1 Ipsen Innovation $150.00 07/17/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076243115
Principal investigator 1 Ipsen Innovation $180.00 06/20/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076247589
Principal investigator 1 Ipsen Innovation $300.00 06/20/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076247591
Principal investigator 1 Ipsen Innovation $300.00 06/20/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076247593
Principal investigator 1 Ipsen Innovation $3,000.00 05/06/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076242319
Principal investigator 1 Ipsen Innovation $2,000.00 04/17/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076242101
Principal investigator 1 Ipsen Innovation $1,000.00 04/17/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076242103
Principal investigator 1 Ipsen Innovation $10,000.00 04/17/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076242105
Principal investigator 1 Ipsen Innovation $1,750.00 04/17/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076242109
Principal investigator 1 Ipsen Innovation $750.00 04/15/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076242107
Principal investigator 1 Ipsen Innovation $500.00 04/15/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076242111
Principal investigator 1 Ipsen Innovation $3,000.00 04/15/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076242113
Principal investigator 1 Ipsen Innovation $1,000.00 03/15/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076241939
Principal investigator 1 Ipsen Innovation $2,000.00 03/15/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076245901
Principal investigator 1 Ipsen Innovation $1,750.00 03/15/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076245907
Principal investigator 1 Ipsen Innovation $10,000.00 03/15/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076245909
Principal investigator 1 Ipsen Innovation $750.00 03/11/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076245903
Principal investigator 1 Ipsen Innovation $500.00 03/11/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076245905
Principal investigator 1 Ipsen Innovation $36.43 02/20/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1076242733
Principal investigator 1 Ipsen Innovation $36.43 02/02/2024 Non-covered Recipient Entity
North Texas Institute Of Neurology And Headache
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Episodic Migraine in Adult Participants No dispute reported 06/30/2026 1076241375